Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy.

Jeovanna LowePeter KolkhofMichael J HauptKyra K PeczkowskiNeha RastogiJ Spencer HauckFeni K KadakiaJonathan G ZinsPierce C CicconeSuzanne SmartPeter SandnerSubha V RamanPaul M L JanssenJill A Rafael-Fortney

Published in: ESC heart failure (2020)

Finerenone administered as a monotherapy is disease modifying for both skeletal muscle and heart in a preclinical DMD model. These findings support further evaluation of finerenone in DMD clinical trials.

Keyphrases

muscular dystrophy
duchenne muscular dystrophy
skeletal muscle
clinical trial
cell therapy
insulin resistance
open label
heart failure
combination therapy
atrial fibrillation
metabolic syndrome
binding protein
study protocol